WHO Launches Groundbreaking Online Repository for Evidence-Informed Decision-Making Tools

By HEOR Staff Writer

September 19, 2023

Evidence-Informed Decision-Making

The World Health Organization (WHO) has launched an innovative online repository of Evidence-Informed Decision-Making (EIDM) tools. This pioneering platform, the first of its kind, showcases WHO tools and external tools used by WHO to facilitate knowledge translation. It also highlights partner organisations involved in planning, managing, monitoring, and evaluating the process of evidence use and implementation.

Developed by the Evidence to Policy and Impact Unit of the Research for Health Department in the Science Division, in collaboration with the Evidence-Informed Policy Network (EVIPNet), the repository supports the unit’s EIDM capacity-sharing work. The platform complements the WHO evidence ecosystem framework published last year, specifically focusing on the policy/action cycle.

Navigating the Online Platform

The user-friendly online platform enables users to search and access EIDM methods and tools corresponding to each step of the policy/action cycle. Users can refine their searches using advanced functionalities to filter by document type, language, and publication date. The platform offers tools that span the clinical (or practice), public health, and health system domains.

Currently, the repository houses and maintains 75 tools, with continuous updates as new tools emerge. The Evidence to Policy and Impact Unit plans to actively add more tools to the repository, employing a scoping literature review and other steps.

The ultimate goal of EIDM and the work of EVIPNet is to support WHO staff and Member States in applying rigorous, systematic, and transparent methods for the creation and application of research evidence in their day-to-day work. This will enable the organisation to successfully achieve the “Triple Billion” targets: a billion more people with universal health coverage, a billion more people protected from health emergencies, and a billion more people with better health and well-being.

Reference url

Recent Posts

TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New Era in Cardiovascular...

By João L. Carapinha

March 19, 2026

The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes transcatheter aortic valve implantation (TAVI) in...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
The PRIME Scheme Evaluation of the European Medicines Agency’s (EMA) PRIority Medicines (PRIME), launched in 2016, confirms early and enhanced regulatory support accelerates medicines for unmet needs. A two-year pilot (April 2023–March 2025) tested three new features—regulatory roadmap and produc...
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy

By João L. Carapinha

March 17, 2026

Imfinzi gastric cancer treatment has received European Commission approval for adults with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. AstraZeneca’s Imfinzi (durvalumab), a PD-L1 inhibitor, combined with FLOT chemotherapy...